StockNews.AI

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA

StockNews.AI • 3 hours

APLSAVPT
High Materiality9/10

Information

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves...

Original source

AI Summary

Vanda Pharmaceuticals is facing a class action investigation for potential securities fraud following the FDA's rejection of its drug HETLIOZ for jet lag treatment, citing inadequate clinical trial evidence. This news led to a significant drop in Vanda's stock price, raising concerns among investors about the company's management and future prospects.

Sentiment Rationale

Historically, stocks facing FDA rejections and investigations often see continuing declines. Vanda's recent struggles with FDA and legal scrutiny indicate major operational weaknesses.

Trading Thesis

VNDA stock is likely to experience further downward pressure in the short term.

Market-Moving

  • FDA's rejection of HETLIOZ could severely impact Vanda's revenue projections.
  • The ongoing investigation into securities fraud may deter new investors.
  • Market sentiment is bearish amidst heightened scrutiny and potential legal ramifications.

Key Facts

  • Pomerantz LLP is investigating potential securities fraud at Vanda Pharmaceuticals.
  • Vanda's drug HETLIOZ received an FDA rejection for treating jet lag disorder.
  • FDA cited inadequate clinical trial evidence regarding drug effectiveness.
  • Vanda's stock dropped 14.05% after the FDA decision announcement.
  • Investors are advised to contact Pomerantz regarding the investigation.

Companies Mentioned

  • Vanda Pharmaceuticals (VNDA): Facing FDA rejection and fraud investigation.
  • Pomerantz LLP: Leading the securities fraud investigation into Vanda.

Corporate Developments

This content fits within 'Corporate Developments' as it involves significant issues about Vanda's business practices and regulatory proceedings, which could heavily impact investor confidence and stock performance.

Investor Alert: Pomerantz Law Firm Investigates Claims on Behalf of Vanda Pharmaceuticals Inc. (VNDA) Investors

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) — Pomerantz LLP has initiated an investigation into claims concerning Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) and its executive management. Investors are encouraged to contact Danielle Peyton at newaction@pomlaw.com or call 646-581-9980, ext. 7980 for more information regarding the investigation into possible securities fraud or unlawful business practices involving the Company.

Recent FDA Decision Affects Vanda Pharmaceuticals' Stock

On January 8, 2026, Vanda Pharmaceuticals issued a press release noting the receipt of a decision letter from the U.S. Food and Drug Administration (FDA) regarding the supplemental New Drug Application (sNDA) for HETLIOZ® (tasimelteon), targeting the treatment of jet lag disorder. The FDA stated that it could not approve the application in its current format.

This announcement has significant implications for Vanda Pharmaceuticals and its shareholders. The FDA recognized positive efficacy from Vanda's controlled clinical trials but concluded that these data did not present substantial evidence of effectiveness for jet lag disorder. Specifically, the FDA indicated that the protocols utilized in the trials (5-hour and 8-hour bedtime shifts) are not sufficiently comparable to actual jet travel, which entails additional variables like

  • Reduced oxygen pressure
  • Physical constraints
  • Noise interference
  • Lighting variations

Impact on VNDA Stock Performance

Following the FDA decision, shares of Vanda Pharmaceuticals experienced a notable decline. On January 8, 2026, the stock price dropped by $1.20, translating to a 14.05% decrease, ultimately closing at $7.34 per share. This decline underscores investor concerns regarding the company's future prospects in the wake of regulatory challenges.

Pomerantz LLP: A Leader in Securities Litigation

Pomerantz LLP is recognized as one of the foremost firms specializing in corporate, securities, and antitrust class action litigation. With offices spanning major cities, including New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, the firm has a storied history that dates back over 85 years. Founded by the esteemed Abraham L. Pomerantz, the firm has consistently advocated for victims of securities fraud, breaches of fiduciary duty, and corporate misconduct, achieving numerous multimillion-dollar settlements for class members.

For more information on Vanda Pharmaceuticals and potential claims, visit www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information

For inquiries, please contact:

Danielle Peyton
Pomerantz LLP
Email: dpeyton@pomlaw.com
Phone: 646-581-9980 ext. 7980

Related News